TRANSTHERA-B (02617) Announces Clinical Data for Tienigotinib Monotherapy in Advanced Cholangiocarcinoma Patients at 2026 ASCO GI Symposium

Stock News01-12

TRANSTHERA-B (02617) announced that the company presented clinical data for its core product, Tienigotinib, as a monotherapy for patients with advanced cholangiocarcinoma (CCA) in a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The presentation was titled: A Phase II Study of Tienigotinib in Advanced Cholangiocarcinoma: Analysis of Molecular Response and Resistance Mechanisms. FGFR inhibitors have an established role in treating cholangiocarcinoma with FGFR2 alterations. Tienigotinib, a novel FGFR inhibitor, has demonstrated promising activity in overcoming acquired resistance to prior FGFR inhibitor therapy. This report detailed circulating tumor DNA (ctDNA) biomarker analyses, evaluating Tienigotinib's efficacy in treating CCA patients with FGFR2 fusions and primary resistance to FGFR inhibitors, those with FGFR2 fusions and acquired resistance to FGFR inhibitors, as well as patients with other FGFR mutations or wild-type FGFR. The analysis assessed genomic alterations in patient ctDNA and performed a correlation analysis of efficacy based on ctDNA mutation status and patient subgroups. These results support further in-depth investigation through expanded biomarker sampling in the ongoing Phase III clinical trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111791023?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 07:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111791023","market":"fut","top_or_hot":-1,"title":"TRANSTHERA-B (02617) Announces Clinical Data for Tienigotinib Monotherapy in Advanced Cholangiocarcinoma Patients at 2026 ASCO GI Symposium","media":"Stock News","content":"<p>TRANSTHERA-B (02617) announced that the company presented clinical data for its core product, Tienigotinib, as a monotherapy for patients with advanced cholangiocarcinoma (CCA) in a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The presentation was titled: A Phase II Study of Tienigotinib in Advanced Cholangiocarcinoma: Analysis of Molecular Response and Resistance Mechanisms. FGFR inhibitors have an established role in treating cholangiocarcinoma with FGFR2 alterations. Tienigotinib, a novel FGFR inhibitor, has demonstrated promising activity in overcoming acquired resistance to prior FGFR inhibitor therapy. This report detailed circulating tumor DNA (ctDNA) biomarker analyses, evaluating Tienigotinib's efficacy in treating CCA patients with FGFR2 fusions and primary resistance to FGFR inhibitors, those with FGFR2 fusions and acquired resistance to FGFR inhibitors, as well as patients with other FGFR mutations or wild-type FGFR. The analysis assessed genomic alterations in patient ctDNA and performed a correlation analysis of efficacy based on ctDNA mutation status and patient subgroups. These results support further in-depth investigation through expanded biomarker sampling in the ongoing Phase III clinical trial.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B (02617) Announces Clinical Data for Tienigotinib Monotherapy in Advanced Cholangiocarcinoma Patients at 2026 ASCO GI Symposium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B (02617) Announces Clinical Data for Tienigotinib Monotherapy in Advanced Cholangiocarcinoma Patients at 2026 ASCO GI Symposium\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-12 07:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TRANSTHERA-B (02617) announced that the company presented clinical data for its core product, Tienigotinib, as a monotherapy for patients with advanced cholangiocarcinoma (CCA) in a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The presentation was titled: A Phase II Study of Tienigotinib in Advanced Cholangiocarcinoma: Analysis of Molecular Response and Resistance Mechanisms. FGFR inhibitors have an established role in treating cholangiocarcinoma with FGFR2 alterations. Tienigotinib, a novel FGFR inhibitor, has demonstrated promising activity in overcoming acquired resistance to prior FGFR inhibitor therapy. This report detailed circulating tumor DNA (ctDNA) biomarker analyses, evaluating Tienigotinib's efficacy in treating CCA patients with FGFR2 fusions and primary resistance to FGFR inhibitors, those with FGFR2 fusions and acquired resistance to FGFR inhibitors, as well as patients with other FGFR mutations or wild-type FGFR. The analysis assessed genomic alterations in patient ctDNA and performed a correlation analysis of efficacy based on ctDNA mutation status and patient subgroups. These results support further in-depth investigation through expanded biomarker sampling in the ongoing Phase III clinical trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1111791023","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111791023","pubTimestamp":1768173258,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TRANSTHERA-B (02617) announced that the company presented clinical data for its core product, Tienigotinib, as a monotherapy for patients with advanced cholangiocarcinoma (CCA) in a poster session at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02617":"药捷安康-B"},"translate_title":"Tranthera-B(02617)在2026年ASCO GI研讨会上公布Tienigotinib单药治疗晚期胆管癌患者的临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"TRANSTHERA-B (02617) announced that the company presented clinical data for its core product, Tienigotinib, as a monotherapy for patients with advanced cholangiocarcinoma (CCA) in a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The presentation was titled: A Phase II Study of Tienigotinib in Advanced Cholangiocarcinoma: Analysis of Molecular Response and Resistance Mechanisms. FGFR inhibitors have an established role in treating cholangiocarcinoma with FGFR2 alterations. Tienigotinib, a novel FGFR inhibitor, has demonstrated promising activity in overcoming acquired resistance to prior FGFR inhibitor therapy. This report detailed circulating tumor DNA (ctDNA) biomarker analyses, evaluating Tienigotinib's efficacy in treating CCA patients with FGFR2 fusions and primary resistance to FGFR inhibitors, those with FGFR2 fusions and acquired resistance to FGFR inhibitors, as well as patients with other FGFR mutations or wild-type FGFR. The analysis assessed genomic alterations in patient ctDNA and performed a correlation analysis of efficacy based on ctDNA mutation status and patient subgroups. These results support further in-depth investigation through expanded biomarker sampling in the ongoing Phase III clinical trial.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111791023","isCrawlerRequest":true}